ZD 0473

Known as: ZD-0473, ZD0473 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2010
051019992010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
We present the method of theoretical calculations of the Raman intensities and the simulated Raman spectra of platinum(II… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
2004
2004
Purpose: ZD0473 (AMD473) [cis-amminedichloro(2-methylpyridine) platinum(II)] is a novel platinum agent of proven activity in… (More)
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2002
2002
ZD0473 is a new generation platinum agent that, in preclinical studies, shows evidence of an extended spectrum of anti-tumor… (More)
Is this relevant?
2002
2002
A phase II, open-label, non-comparative, multicentre trial of the platinum analogue ZD0473 as second-line therapy for pleural… (More)
Is this relevant?
2002
2002
ZD0473 is a new generation hindered platinum agent currently undergoing worldwide Phase II clinical studies. The in vitro… (More)
Is this relevant?
2002
2002
The primary aim of this phase II trial was to assess the antitumour activity of ZD0473 in ovarian cancer patients who had failed… (More)
Is this relevant?
2000
2000
Wild-type p53 is frequently mutated in late-stage ovarian cancer and has been proposed as a determinant of cisplatin… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2000
2000
Acquired drug resistance to the sterically hindered platinum drug ZD0473 (formerly known as JM473 and AMD473) and currently being… (More)
Is this relevant?
2000
2000
ZD-0473 (formerly JM-473 and AMD-473) is a sterically hindered platinum (II) complex designed and synthesized by Johnson Matthey… (More)
Is this relevant?
2000
2000
Platinum drugs play an important role in the treatment of cancer, but there is room for improvement. Here we present a new… (More)
Is this relevant?